3. Duplicative Therapy

Using two or more serotonin 5-HT_1B/1D receptor agonists concurrently is not justified due to lack of additional therapeutic benefit and the potential for additive vasospastic effects. Patient profiles documenting receipt of multiple serotonin 5-HT_1B/1D receptor agonists will be reviewed.